Honest Opinion?
1B would need Phase 3 trials for at least one of the 4 novel drugs.
Thats it. FDA EUA for ARDS would be massive but 1B is quite the hefty valuation. Even with hype I wouldnt bet on it... Going down the pathway though if the drug is proven to work in human trials etc and works on patients suffering from COVID-19 then we can start to talk about these kind of numbers.
P3 is not that far off honestly and IHLs OSA and TBI drugs have been advised by Camargo to be candidates for the FDA fast track route to take the drug to market.
Successful Phase 2B in our imminent OSA trial would mean Phase 3 would be planned. If that is also successful... commercialization is the next step.
Which would justify 1B MC+ for sure.
Add to My Watchlist
What is My Watchlist?